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Abstract:  The  renin–angiotensin–aldosterone  system  (RAAS),  an  important  regulator  of 
blood  pressure  and  mediator  of  hypertension-related  complications,  is  a  prime  target  for 
cardiovascular drug therapy. Angiotensin-converting enzyme inhibitors (ACEIs) were the first 
drugs to be used to block the RAAS. Angiotensin II receptor blockers (ARBs) have also been 
shown to be equally effective for treatment. Although these drugs are highly effective and are 
widely used in the management of hypertension, current treatment regimens with ACEIs and 
ARBs are unable to completely suppress the RAAS. Combinations of ACEIs and ARBs have 
been shown to be superior than to either agent alone for some, but certainly not all, composite 
cardiovascular and kidney outcomes, but dual RAAS blockade with the combination of an 
ACEI and an ARB is sometimes associated with an increase in the risk for adverse events, 
primarily hyperkalemia and worsening renal function. The recent introduction of the direct 
renin inhibitor, aliskiren, has made available new combination strategies to obtain a more 
complete blockade of the RAAS with fewer adverse events. Renin system blockade with 
aliskiren and another RAAS agent has been, and still is, the subject of many large-scale clinical 
trials and furthermore, is already available in some countries as a fixed combination.
Keywords: angiotensin II receptor blockers, renin–angiotensin–aldosterone system, 
hypertension, angiotensin-converting enzyme inhibitors
Introduction: the blockade of the renin–
angiotensin–aldosterone system
In the last decades, renin–angiotensin–aldosterone system (RAAS) has become, unques-
tionably, a key point in the pathophysiology of cardiovascular and kidney diseases.
Activation of the RAAS occurs following the release of renin by the kidney. Renin 
is a proteinase enzyme that catalyzes cleavage of angiotensinogen to form angiotensin 
I (Ang I). Ang I is itself inactive but is converted to the biologically active peptide 
angiotensin II (Ang II) by angiotensin-converting enzyme (ACE), which is produced 
in the lungs and cleaves the Ang I molecule.
Ang II binds with the type 1 Ang II receptors (AT1) in the smooth muscle cells of 
the peripheral blood vessels causing vasoconstriction, and hence increased peripheral 
vascular resistance and increased blood pressure (BP; Figure 1). Ang II is recognized to 
be a major contributor to the progression of cardiovascular and kidney diseases.1–4
Activation of AT1 receptors by Ang II also stimulates release of the mineralocorti-
coid, aldosterone, from the adrenal gland, situated superior to the kidney. Aldosterone 
promotes sodium and water retention along the nephron, further increasing the BP.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Plasma renin activity (PRA) is a measure of the level of 
activity in the RAAS, and consequently, it can be used as an 
indicator to detect dysregulation of the RAAS. As a matter of 
fact, PRA reflects the capacity of circulating renin to cleave 
angiotensinogen to form Ang I, and thus provides a measure 
of the level of activity in the RAAS.
The RAAS is targeted at different places by the   existing 
antihypertensive therapies. Angiotensin-converting enzyme 
inhibitors (ACEIs) reduce the production of Ang II by inhib-
iting the conversion of Ang I to Ang II by these enzymes. 
Angiotensin receptor blockers (ARBs) antagonize AT1 
receptors and prevent Ang II from binding. However, 
ACEIs and ARBs are associated with a feedback loop that 
increases PRA, as loss of stimulation of AT1 receptors on 
juxtaglomerular cells in the kidney (ie, removal of negative 
feedback) leads to a compensatory increase in renin release. 
The resulting increase in PRA may limit the organ protection 
offered by these drugs5 (Figure 1).
The whole RAAS is, therefore, upregulated although 
AT1 receptor-mediated effects of the effector molecule 
Ang II are blocked. Direct renin inhibitors (DRI) target the 
RAAS at its point of activation, resulting in the reduction 
of PRA (Figure 2).
As DRI reduces PRA, the production of Ang I decreases, 
resulting in less substrate availability for conversion to Ang II 
by ACE or other enzymes. In doing so, direct renin inhibition 
produces effective overall RAAS suppression.5
The functional renin receptor plays a pivotal role in 
Ang II production and cellular responses to renin. The 
binding of renin to its receptor triggers intracellular signals 
by rapid activation of mitogen-activated protein kinases, 
ie, extracellular signal-regulated protein kinases 1 and 2, 
and may increase plasma activator inhibitor-1 – a pro-
thrombotic agent – levels via this mechanism. Furthermore, 
the bound renin has increased catalytic efficiency for the 
cleavage of angiotensinogen to form Ang I, facilitating 
Ang II production (by ACE or vascular muscle smooth 
chymase) at the cell surface. This may have consequences 
in terms of organ damage and progression of cardiovascular 
disease.6,7
It is now clear that the blockade of the RAAS not only 
reduces the BP but also decreases the risk of cardiovascular 
events and slows the progression of renal disease in   different 
types of patients.8–11 Nevertheless, some patients do not 
respond adequately to the conventional renin–angiotensin 
system blockade, raising a clinical problem that qualifies 
the patient still at high risk for cardiovascular or renal dis-
eases; in a significant number of patients, in fact, even if 
the target of lowering BP is obtained, the RAAS blockade 
with an ACE inhibitor or an ARB does not reduce the risk 
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Figure 1 ACeis and ARBs cause compensatory increases in PRA. 
Abbreviations: ACe, angiotensin-converting enzyme; ACeis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; PRA, plasma renin activity; 
Ang i, angiotensin i; Ang ii, angiotensin ii; AT1, type 1 Ang ii receptor.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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of experiencing cardiovascular events and chronic heart and 
kidney disease progress despite the therapy.9,12–16 Incomplete 
blockade of the RAAS at recommended doses may be one 
explanation for this observation.17,18 Not withstanding the 
evolution from ACE inhibitors to ARBs, the RAAS will 
not be fully blocked using just these molecules alone.17,19,20 
Accordingly, one strategy to improve the efficacy of RAAS 
blockade is to combine ACEIs and ARBs. ACEIs and ARBs 
combination has been widely studied in patients with hyper-
tension, nephropathy, diabetes, myocardial infarction (MI), 
and heart failure.21
This review intends to examine the rationale for RAAS 
blockade at different levels using combinations of different 
molecules acting on this system; we will consider at first 
the characteristics of ACEI/ARBs combinations, following 
a pathway that will bring us to the actual use of DRIs alone 
or in fixed combination with ARBs.
ACEI/ARB combination therapy
Although the theoretical benefits of combined ACEI-
based and ARB-based therapy may enhance BP control 
and improve clinical outcomes in some subpopulations 
of patients, in 2006, Weber and Giles22 already observed 
that, for the most patients, these RAAS-based therapies do 
not reduce the risk for major cardiovascular events to the 
expected extent based on the vital role of the RAAS in the 
pathophysiology of hypertension and cardiorenal disease. 
They speculated that this may indicate that the RAAS is 
not as widely dysregulated in hypertension as previously 
believed, or that the current strategies and/or agents avail-
able for RAAS suppression are not as effective as they 
could or should be. With respect to the latter argument, 
dual RAAS blockade at different sites in the RAAS path-
way theoretically would have provided additive protective 
effects by further reducing systemic and local levels of 
some or all angiotensin peptides, which could further inhibit 
formation of the Ang II.23–26 On the same topic, combina-
tions of ACEIs and ARBs have generally been shown to 
produce small but significant additional reductions in BP 
compared with either monotherapy;27,28 although several 
studies have shown that ACEI/ARB combinations result 
in modest improvement in BP and proteinuria compared 
with treatment with only one of these drug classes,2,13,29–31 
others do not support this combination because of concerns 
about efficacy (modest improvement in BP with limited 
or no additional benefit on outcomes) and safety.32 For 
instance, in a crossover study of 64 hypertensive patients not 
  achieving BP control with full-dose valsartan, the addition 
of amlodipine reduced ambulatory 24-hour BP to a greater 
extent than the addition of benazepril (−15.2/−9.9 mmHg 
vs −8.6/−6.3 mmHg, respectively).33   Similarly, ACEI/
ARB combination therapy was less effective for lowering 
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Figure 2 Direct renin inhibition acts at the point of activation of the renin system and neutralizes the PRA increase. 
Abbreviations: ACe, angiotensin-converting enzyme; PRA, plasma renin activity; Ang i, angiotensin i; Ang ii, angiotensin ii; AT1, type 1 Ang ii receptor.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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BP than ARB/thiazide diuretic combination therapy in a 
study of 327 hypertensive patients uncontrolled by ARB 
monotherapy34 and in a study of 88 African Americans with 
hypertension.35
The Valsartan in Acute Myocardial Infarction (VALIANT) 
study of 14,703 elderly patients with left ventricular systolic 
dysfunction, congestive heart failure (CHF), or both after 
MI reported similar rates of all-cause mortality, death from 
cardiovascular events, recurrent MI, and hospitalization for 
heart failure for all three of its   treatment groups (ACEI, ARB, 
and ACEI/ARB), accompanied by significantly (P , 0.05) 
more adverse events in the   combination therapy group.36
Two meta-analyses of patients with CHF or left ventricu-
lar dystrophy (LVD; including CHARM-Added, Val-HeFT, 
and VALIANT) yet showed that ACEI/ARB combination 
therapy significantly increases the risk for adverse events 
(eg, hypertension, worsening renal function, and hyper-
kalemia), inducing treatment discontinuation.37,38 On the 
other hand, in the Randomized Evaluation of Strategies 
for Left Ventricular Dysfunction pilot study,39 ACEI/ARB 
combination therapy, compared with   monotherapy, signifi-
cantly limited the increases in end-diastolic and   end-systolic 
volumes (P , 0.01) and reduced brain   natriuretic peptide, 
a biomarker of heart failure.40 Again in the Candesartan in 
Heart Failure: Assessment of Reduction in   Mortality and 
Morbidity trial30 after a median follow-up of 41 months, 
fewer patients taking the ACEI/ARB combination 
(38%), compared with those receiving ACEI plus placebo 
(42%), experienced the primary composite end point of 
cardiovascular death or hospitalization for chronic heart 
failure (P = 0.01).
However, some recent large trials have failed to find 
  better cardiovascular outcomes with the ACEI/ARB com-
bination despite better BP reductions.
The Valsartan Heart Failure Trial41 determined whether 
valsartan could further reduce morbidity and mortality 
in patients with heart failure, who already receiving 
optimal therapy (including ACEIs in 93% of patients and 
β-blockers in 35% of patients). The primary end point of 
mortality was similar for the valsartan and placebo groups, 
whereas the combined primary end point of morbidity 
and mortality was significantly reduced (P = 0.009) in 
patients receiving valsartan plus optimal therapy compared 
with the placebo group. This benefit was primarily due 
to a 24% reduction in hospitalizations for heart failure in 
valsartan-treated patients. A subgroup analysis of patients 
on different background therapies revealed that valsartan 
had a favorable effect on the combined primary end point 
in those receiving an ACEI (P = 0.002), a β-blocker 
(P = 0.037), or no background therapy (P = 0.003). In con-
trast, in patients receiving both an ACEI and a β-blocker, 
valsartan had an adverse effect on mortality (P = 0.009), 
suggesting that this particular approach to comprehensive 
blockade of neurohormone systems in heart failure may 
be detrimental.41
In the Ongoing Telmisartan Alone and in Combination 
With Ramipril Global Endpoint Trial,28 combination therapy 
with telmisartan plus ramipril produced no greater   reduction 
in the primary end point of death from cardiovascular 
events, MI, stroke, or hospitalization for heart failure than 
either component monotherapy in high-risk patients with 
cardiovascular disease or diabetes but without heart   failure. 
  Combination therapy was associated with an increased 
risk of hypotension (P , 0.001), syncope (P = 0.03), 
hyperkalemia (P , 0.001), and acute renal impairment 
(P , 0.001). The reasons for the lack of additional benefits 
with combination therapy, despite an additional reduction 
in systolic BP of 3.4 mmHg, compared with ACEI mono-
therapy are unknown. As the investigators pointed out, the 
majority of patients were also receiving statins, β-blockers, 
and antiplatelet medications so that additional RAAS block-
ade with the ACEI/ARB combination therapy resulted in 
little additional clinical benefit compared with the ACEI 
therapy alone.28
Although it is clear that monotherapy with ACE 
inhibitors or ARBs is effective in reducing cardiovascular 
mortality and morbidity in patients with heart failure, the 
reasons for the different cardiovascular outcomes in trials 
examining ACEI/ARB combinations may relate to differ-
ent patient populations, previous or concurrent successful 
treatment with other drugs, or study design. As noted by 
Arici and Erdem,32 many clinical studies have been small 
and of short duration, and most used submaximal doses 
of ACEIs and ARBs both alone and in combination. Most 
combination studies were not designed to maximize BP con-
trol and in fact, achieved only modest improvement in BP 
(∼3−4 mmHg) over monotherapy with an ACEI or ARB.42 
In addition, many early studies used once-daily dosing with 
short-acting ACEIs. Therefore, it is possible that low ACEI 
concentrations at trough in combination studies using short-
acting ACEIs could have increased the likelihood of both 
acute (method related) and chronic (mechanistic mediated) 
ACE escape. Administration of diuretics also has resulted 
in increases in PRA,43 and the use of diuretics as concurrent Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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medications usually is permitted in ACEI and ARB studies. 
Increases in both PRA and ACE escape have been associ-
ated with adverse clinical outcomes in patients on ACEI or 
ARB therapy. For example, in a study of 70 patients with 
CHF, elevated PRA despite 6 months of treatment with 
an ACEI was an independent predictor of elevated Ang 
II levels (P = 0.0004), and elevated plasma Ang II levels 
were an independent predictor of death or worsening CHF 
(P = 0.002).44 In another study, 699 patients with CHF 
underwent a complete clinical and biochemical workup at 
baseline and were monitored for a median of 23 months; 
81% of them were receiving an ACEI or ARB.45 Elevated 
baseline PRA was an independent predictor of death or 
the need for cardioversion in patients with implantable 
cardioverter devices (P , 0.001), and PRA was higher in 
patients on RAAS inhibitors relative to those not receiv-
ing RAAS inhibitors (P = 0.017). In Val-HeFT, analysis 
of 4,300 patients with CHF, who had neurohormonal 
measurements, showed that increased baseline PRA was an 
independent predictor of all-cause mortality (P = 0.011) and 
of combined mortality and morbidity (P = 0.0025).46 This 
was observed despite the fact that the majority of patients 
were receiving treatment with an ACEI and approximately 
50% were also receiving treatment with an ARB. A recent 
post hoc analysis of Val-HeFT data showed that PRA was 
3.7 times higher in patients receiving ACEIs (vs those 
not receiving them), and that higher PRA at baseline was 
associated with greater mortality among patients receiving 
ACEIs (P = 0.0005).47
All together, these findings strongly indicate that PRA 
is related to adverse clinical outcomes even for patients 
receiving treatment with ACEIs and/or ARBs and further 
raises the possibility that DRIs may be useful alone or in 
combination with ACEIs or ARBs for reducing the risk for 
these outcomes.
Direct renin inhibitor
Pharmacokinetic and pharmacodynamic
Aliskiren, an octanamide, is the first representative of a new 
class of nonpeptide, low molecular weight, orally effective 
transition-state renin inhibitors.48–50 It is a DRI that has a 
high binding affinity for renin, and this may be explained 
by a number of interactions with the enzyme’s active site. In 
healthy humans, aliskiren of doses between 40 and 640 mg 
exerts a dose-dependent reduction in PRA, Ang I, and 
Ang II levels. The molecule is superior in reducing PRA 
compared with ARBs. Again, aliskiren at a dose of 300 mg 
decreases PRA in hypertensive patients by approximately 
50%–80%51,52 and reduces PRA and plasma levels of Ang I 
and Ang II for 48 hours.53 Furthermore, urinary aldosterone 
was reduced at a dose of 80 mg or more, and sodium extrac-
tion was increased to 91% at a dose of 640 mg.54 Compared 
with valsartan, aliskiren more strongly decreases the activ-
ity of renin in the circulation and reduces the excretion of 
urinary aldosterone for a longer period.53,55 Following oral 
administration, peak plasma concentrations of aliskiren are 
reached within 1–3 hours.52,53,56–58 The plasma half-life of 
aliskiren in humans shows a slow terminal elimination at 
23–70 hours59–61 and approximately 47%–51% of aliskiren 
is bound by plasma proteins in humans, independent of the 
concentration.59,62,63 Based on in vitro studies, the major 
enzyme responsible for its metabolism appears to be 
Cytochrome P450 (CYP3A4). Aliskiren does not inhibit 
the CYP450 isoenzymes (CYP1A2, CYP2C8, CYP2C19, 
CYP2D6, CYP2E1, and CYP3A), and the main elimina-
tion route of aliskiren is via feces in its unmetabolized 
form.64 Approximately one-fourth of the absorbed dose 
also appears in the urine as unchanged compound; the 
pharmacokinetic and pharmacodynamic differences of 
aliskiren between Caucasians and Japanese are minimal 
and no clinically important pharmacokinetic differences 
were observed between patients with type 2 diabetes and 
normal population: the half-life of this drug was 40 hours 
and 44 hours in healthy subjects and patients with diabetes, 
respectively.58,61
Clinical features
Aliskiren is well tolerated by all age groups, including the 
very elderly, and there are no indications to change the 
recommended dose of aliskiren in patients with hepatic and 
renal insufficiency because the peak concentration, area 
under the curve (AUC), and half-life were only slightly 
greater in patients with hepatic dysfunction.52 Aliskiren 
exposure was also increased slightly in patients with renal 
function impairment, but these changes did not correlate 
with creatinine clearance.62 All agents that inhibit the 
RAAS activate the negative feedback loop that leads to 
a compensatory increase in plasma renin concentration. 
When this increase occurs during treatment with ACEIs 
and ARBs, the result is increased levels of PRA but   during 
treatment with aliskiren, the effect of increased renin levels 
is blocked, so the levels of Ang I and Ang II, as well as 
PRA, are all reduced.52 The clinical trials do not report any 
major adverse effects of aliskiren compared with ARBs or Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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ACEs being generally well tolerated by all patients. The 
most common adverse events of aliskiren are diarrhea, 
headache, nasopharyngitis, dizziness, fatigue, back pain, 
gastrointestinal disorders, rash, and renal stones.52,55,62,65 
Because aliskiren directly inhibits the RAAS, theoretically 
adverse events such as coughing and angioedema may also 
occur; as a matter of fact, few cases of edema involving 
the face, lips, tongue, hands, and whole body have been 
reported to involve more than 1% of patients treated with 
aliskiren, which also occur at a similar or greater extent 
in patients receiving placebo.52,62,65 Aliskiren has the same 
contraindications as ACEIs and ARBs, including hypersen-
sitivity reactions to the molecule, pregnancy, and bilateral 
renal-artery stenosis.
Nussberger et al56 first reported the clinical effects of 
aliskiren compared with enalapril and placebo. Subjects 
were randomized into three 8-day treatments with enalapril 
20 mg/d or placebo, aliskiren 40 or 160 mg/d, and aliskiren 
80 or 640 mg/d.
Aliskiren produced dose-dependent reductions in PRA, 
Ang I, and Ang II vs placebo. Inhibition of Ang II produc-
tion on day 8 was superior to that of placebo with aliskiren 
160 mg, aliskiren 640 mg, and enalapril. Reductions in plasma 
and urine aldosterone concentrations were similar between 
enalapril and aliskiren doses greater than 40 mg/d. All subjects 
were normotensive upon enrollment, and no changes in BP or 
heart rate were observed. Adverse events were similar among 
all treatment groups, including enalapril and placebo. Orthos-
tasis and dizziness following blood draws were reported in all 
treatment groups, with a tendency toward increased dizziness 
with aliskiren 640 mg (actual incidence not reported).
Stanton and colleagues66 performed a randomized, 
double-blind, parallel-group study in 226 patients aged 
21–70 years with mild to moderate essential hypertension 
comparing the 4-week BP-lowering effects and safety of 
aliskiren 37.5, 75, 150, and 300 mg/d with those of losartan 
100 mg/d and showed dose-dependent decreases in daytime 
ambulatory systolic BP and PRA in patients treated with 
aliskiren. There was no difference in BP lowering of day-
time ambulatory systolic BP between aliskiren 75, 150, and 
300 mg/d and losartan 100 mg/d. The BP-lowering activity 
of the 300 mg dose persisted for 24 hours. With aliskiren, 
PRA fell dose-dependently by 50%–80%, whereas it doubled 
with losartan. The authors concluded that aliskiren, through 
inhibition of renin, was an effective and safe orally active 
BP-lowering drug.66
In a double-blind, randomized parallel-group trial, 
  Gradman and colleagues67 assigned 652 hypertensive patients 
once-daily doses of 150 mg, 300 mg, or 600 mg aliskiren, 
150 mg irbesartan, or placebo. The reductions in BP (systolic/
diastolic) measured at trough after 8 weeks of follow-up and 
adjusted for baseline values and the difference from placebo 
averaged 6.1/.9, 1.5/.4, 1.4/.2, and 7.2/2.5 mmHg on the 
increasing doses of aliskiren and irbesartan, respectively. The 
2 highest aliskiren doses lowered diastolic BP significantly 
more than irbesartan (P = 0.01). The frequency of adverse 
effects was similar for placebo and aliskiren with the excep-
tion of diarrhea associated with the dose 600 mg/d (1.5% 
vs 6.9%).
Dual blockade DRi/ARB
Because aliskiren is more likely, at least initially, to be 
added into existing therapy than to be used for newly diag-
nosed patients, much of the phase 3 clinical studies have 
investigated its use as add-on therapy to the major classes. 
Indeed, aliskiren has been studied both in comparison to 
and in combination with each of the RAAS-blocking drugs, 
ACEIs, and ARBs.
An early study in healthy human volunteers explored 
the effect of aliskiren in combination with an ARB on com-
ponents of the RAAS, comparing the effects of aliskiren, 
valsartan, and their combination on PRA, Ang II, and 
aldosterone.53 A single dose of 300 mg aliskiren inhibited 
PRA by 95.6% compared with baseline at 4 hours, and it 
remained below placebo for 48 hours (P , 0.05). Similarly, 
Ang II decreased and remained below placebo for 48 hours 
(P , 0.05). In contrast, 160 mg valsartan increased PRA and 
Ang II levels within 4 and 6 hours of dosing, respectively, 
and they were still higher than placebo at 24 and 48 hours 
(P , 0.05). The combination of 150 mg aliskiren and 80 mg 
valsartan decreased PRA below placebo values at 4 hours 
(P , 0.05), with a subsequent return to baseline by 12 hours. 
All the three treatments significantly (P , 0.05) decreased 
plasma levels and urinary excretion of aldosterone for at 
least 4 hours after dosing compared with placebo. Aliskiren 
alone or in combination with valsartan reduced 24-hour 
cumulative urinary aldosterone excretion to a greater extent 
(P , 0.05) than did valsartan alone. Overall, in this study, 
the low-dose combination of aliskiren and valsartan pro-
duced enhanced blockade of the components of the RAAS 
that were equal to those produced by the higher dose of 
aliskiren and higher to those produced by the standard dose 
of valsartan.
The safety and tolerability of dual RAAS blockade with 
aliskiren for treatment of heart failure was examined in the 
Aliskiren Observation of Heart Failure Treatment study Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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(ALOFT).68 In this study, patients (n = 302) were randomized 
to receive aliskiren (150 mg daily) or placebo for 3 months 
in addition to standard therapy. A 98% of the placebo group 
and 99% of the aliskiren group were also receiving an ACEI 
or an ARB. In patients receiving aliskiren, the incidences 
of renal dysfunction,   hypotension, and hyperkalemia were 
similar to placebo. In this study, N-terminal prohormone 
brain natriuretic peptide, an important biomarker of heart 
failure prognosis and the primary efficacy outcome mea-
sure, increased with placebo but decreased with aliskiren 
(P = 0.01). Serum levels of the related biomarker brain natri-
uretic peptide decreased with both placebo and aliskiren, 
ie, to a significantly greater extent with aliskiren than with 
placebo (P = 0.02). Aliskiren also caused a greater reduc-
tion in PRA (P , 0.0001) and 24-hour urinary aldosterone 
excretion (P = 0.02) compared with placebo (Table 1).
In the Aliskiren Left Ventricular Assessment of Hyper-
trophy (ALLAY) study, in which patients with hypertension 
and left-ventricular hypertrophy (LVH) were randomized to 
aliskiren (300 mg), losartan (100 mg), or their combination, 
aliskiren was noninferior to losartan in reducing LV mass 
index, even if the combination was not superior to losartan 
alone.71 These findings suggest that aliskiren is an effective 
and well-tolerated treatment option for patients with LVH. 
The lack of additional benefit with combination therapy may 
be related to the design of the study in which there was no 
significant difference in BP reduction between groups. LV 
mass reduction seems to be directly related to BP reduc-
tion. Tolerability and safety were similar in all treatment 
groups.
In some recent important trials, aliskiren has also shown 
renoprotective potential in patients with type 2 diabetes and 
albuminuria,70,72 the best available surrogate parameter in 
the treatment of diabetic nephropathy, associated with risk 
of renal and cardiovascular events.15,73
In the Aliskiren in the Evaluation of Proteinuria in 
  Diabetes (AVOID) trial, Parving et al70 evaluated the effects 
of dual blockade of the RAAS with aliskiren and losartan in 
patients (n = 599) with hypertension and type 2 diabetes with 
nephropathy. Patients were maintained on losartan (100 mg 
daily) for the duration of the study and were randomized 
to receive a 6-month treatment with aliskiren (150 mg/d 
for 3 months, then 300 mg/d for 3 months) or placebo. 
After 3 months of treatment with aliskiren (150 mg/d), the 
urinary albumin/creatinine ratio (UACR) had decreased by 
11% compared with placebo (P = 0.02). Increasing the dose 
of aliskiren to 300 mg/d caused a further decrease in the 
UACR to 20% (P , 0.001). A nonsignificant difference in 
BP was seen between the treatment groups, suggesting that 
the renoprotective effect of aliskiren was independent of 
Table 1 Aliskiren and ACeis or ARBs combination therapy
Patients N Duration Treatment (mg/d) Results References
Hypertension
Hypertension with  
diabetes
837 8 wk Aliskiren (300) 
Ramipril (10)  
Aliskiren/ramipril (300/10)
−14.7/−11.3a Uresin et al69
Mild-to-moderate  
hypertension
1,797 8 wk Aliskiren (300) 
Valsartan (320) 
Aliskiren/valsartan (300/320)
−13.0/−9.0 
−12.8/−9.7 
−17.2/−12.2
Oparil et al55
Chronic kidney disease
Type 2 diabetes with  
nephropathy
524 6 mo Losartan (100) 
Aliskiren (300) 
Losartan/aliskiren (100/300)
Aliskiren/losartan reduced  
UACR by 20% compared  
with losartan alone
Parving et al70  
The AVOiD Study
Heart failure
NYHA class ii–iV  
heart failure
302 3 mo Aliskiren (150) or placebo  
(plus standard therapy  
including ACeis and ARBs)
Aliskiren decreased plasma  
NT-proBNP and BNP
McMurray et al68  
The ALOFT Study
Left-ventricular  
hypertrophy
Hypertension with  
increased left-ventricular  
wall thickness
465 9 mo Losartan (100) 
Aliskiren (300) 
Losartan/Aliskiren (100/300)
Left-ventricular mass  
reduced to a similar extent  
in all treatment groups
Solomon et al71  
The ALLAY Study
aChange in mean sitting systolic/mean sitting diastolic blood pressure (mmHg).
Abbreviations: ACeis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; UACR, urinary albumin/creatinine ratio; NYHA, New York Heart 
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BP. There was no difference in the rates of adverse events, 
such as hyperkalemia, or discontinuation rates between the 
2 groups.
In a subsequent double-blind, randomized, crossover 
study, 26 patients with type 2 diabetes, hypertension, and 
albuminuria (.100 mg/d) were randomly assigned to four 
2-month treatment periods in random order with placebo, 
300 mg aliskiren once daily, 300 mg irbesartan once daily, 
or the combination of two drugs with identical doses. 
Persson and colleagues74 yet demonstrated that with the 
combination of 300 mg aliskiren and 300 mg irbesartan, 
the reduction in albuminuria was enhanced compared with 
the reduction obtained with the 2 monotherapies. The added 
antiproteinuric effect with combination treatment compared 
with aliskiren alone was 31%.
All these studies suggest that aliskiren plus an ARB may 
provide cardiorenal benefits that go beyond those solely 
attributable to lowering of BP. The DRI approach to RAAS 
suppression is still very recent and the ultimate role of 
aliskiren in combination therapies with ACEIs, ARBs, and 
other antihypertensives will be better defined through future 
studies, which are being conducted as part of the ASPIRE 
HIGHER clinical program.75,76
On the other hand, the dual blockade in post-MI seems 
not be as useful as in the previous reported conditions. As 
a matter of fact, the results of the recently presented study 
ASPIRE77 (designed to test the hypothesis that aliskiren 
on top of standard therapy would improve remodeling in 
post-MI patients with LV dysfunction) have shown the 
following:
•	 The primary end point (LVESV) was nonsignificant; 
however, consistent trends toward smaller ventricles 
were seen in the aliskiren group and early post hoc 
analyses suggest a potential benefit in post-MI patients 
with diabetes.
•	 Secondary composite end points were not different, with 
no statistical difference in any of the components.
•	 There was a nonsignificant trend toward higher mortality 
in the aliskiren group, although total mortality (3%) is 
low compared with the other post-MI trials.
•	 Hyperkalemia, hypotension, and renal dysfunction were 
increased in the aliskiren group overall.
Summarizing, based on echocardiographic markers, the 
ASPIRE study does not support the addition of aliskiren 
to an ACEI or an ARB in post-MI patients with impaired 
left ventricular function. Although early post hoc analyses 
may point toward a beneficial effect in favor of aliskiren in 
some subgroups (eg, patients with diabetes), ASPIRE as a 
hypothesis-generating trial does not support a morbidity and 
mortality study in post-MI patients.
Conclusion
Even though awareness and treatment of hypertension have 
increased over the years, substantial improvements in BP 
control rates are still lacking, with approximately two-thirds 
of hypertensive adults aged 35–64 years failing to reach a BP 
target of ,140/90 mmHg. Nowadays, it is well known that 
the majority of hypertensive patients require 2 or more agents 
to reach BP goal. Not only epidemiological or   observational 
researches but also important and wide clinical trials, 
including Antihypertensive and Lipid-Lowering Treatment 
to Prevent Heart Attack Trial (ALLHAT),  Avoiding Cardio-
vascular Events through Combination Therapy in Patients 
Living with Systolic Hypertension (ACCOMPLISH), The 
International Verapamil SR/Trandolapril Study (INVEST), 
and The Losartan Intervention For Endpoint reduction 
(LIFE), have reported that 23%–54% patients require 3 or 
more antihypertensive agents for BP control and target-level 
maintenance (,140/90 or ,130/80 mmHg depending on 
cardiovascular risk).78–81 In patients with BP $20/10 mmHg 
above goal, on average, 3.2 drugs might be needed to achieve 
BP control.82
The problem of the comorbidity and its consequence – 
the coadministration of multiple drugs – may be substantial 
for elderly patients. In a recent trial conducted by Yarrows 
and colleagues,83,84 the aliskiren/valsartan combination 
therapy had been studied in elderly patients too compared 
with those younger than 65 years of age. The combination 
provided significantly greater reductions in SBP systolic 
BP and BP control rates than did valsartan monotherapy in 
the elderly patients, and the effect of aliskiren/valsartan and 
high-dose valsartan on pulse pressure was greater in elderly 
patients than in younger patients. Aliskiren monotherapy and 
aliskiren/valsartan combinations were equally well tolerated 
in the elderly as in younger patients.
Following the above-reported data and several clinical 
observations, in 2009, the US Food and Drug Administration 
approved the fixed combination of aliskiren/valsartan at the 
dosages of 150/160 mg and 300/320 mg for the treatment of 
hypertension in patients not adequately controlled on aliskiren 
or ARB monotherapy and as initial therapy in patients likely 
to need multiple drugs to achieve their BP goals.
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